ストックスクリーナーアプリを入手
230.11
0.96%
-2.24
アフターアワーズ：
229.89
-0.22
-0.10%
前日終値:
$232.35
開ける：
$230.36
24時間の取引高:
6.13M
Relative Volume:
0.95
時価総額：
$406.87B
収益：
$61.16B
当期純損益:
$4.19B
株価収益率:
97.45
EPS:
2.3614
ネットキャッシュフロー:
$17.82B
1週間 パフォーマンス:
-0.85%
1か月 パフォーマンス:
+2.99%
6か月 パフォーマンス:
+8.26%
1年 パフォーマンス:
+9.19%
1日の値動き範囲:
$226.80
$231.60
1週間の範囲:
$226.80
$237.11
52週間の値動き範囲:
$164.39
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Compare ABBV vs LLY, JNJ, NVS, AZN
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
230.11 | 410.83B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
LLY
Lilly Eli Co
|
990.33 | 878.04B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
240.40 | 577.48B | 94.19B | 26.80B | 19.70B | 11.05 |
|
NVS
Novartis Ag Adr
|
160.12 | 307.23B | 54.72B | 14.02B | 15.32B | 7.1855 |
|
AZN
Astrazeneca Plc
|
194.22 | 306.31B | 58.80B | 10.24B | 8.98B | 3.2788 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-08 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2026-01-07 | 再開されました | UBS | Neutral |
| 2025-12-10 | アップグレード | HSBC Securities | Hold → Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-11-04 | ダウングレード | DZ Bank | Buy → Hold |
| 2025-10-14 | ダウングレード | Erste Group | Buy → Hold |
| 2025-10-01 | ダウングレード | HSBC Securities | Buy → Hold |
| 2025-09-17 | アップグレード | Berenberg | Hold → Buy |
| 2025-08-12 | 再開されました | Piper Sandler | Overweight |
| 2025-08-07 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | ダウングレード | Citigroup | Buy → Neutral |
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-12-05 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-04 | アップグレード | Argus | Hold → Buy |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-06-05 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-05-17 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-01-29 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | ダウングレード | HSBC Securities | Buy → Hold |
| 2023-12-11 | アップグレード | Goldman | Neutral → Buy |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-10-30 | アップグレード | Barclays | Equal Weight → Overweight |
| 2023-10-20 | 再開されました | UBS | Neutral |
| 2023-09-29 | 開始されました | Raymond James | Outperform |
| 2023-07-25 | 開始されました | William Blair | Mkt Perform |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-04-05 | ダウングレード | Argus | Buy → Hold |
| 2023-03-01 | 開始されました | Guggenheim | Buy |
| 2023-02-22 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | アップグレード | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-11-08 | ダウングレード | Societe Generale | Buy → Hold |
| 2022-08-01 | ダウングレード | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Underperform |
| 2022-05-06 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | 再開されました | Morgan Stanley | Overweight |
| 2022-02-28 | ダウングレード | UBS | Buy → Neutral |
| 2022-02-03 | 繰り返されました | BMO Capital Markets | Outperform |
| 2022-02-03 | 繰り返されました | Barclays | Equal Weight |
| 2022-02-03 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-03 | 繰り返されました | Goldman | Neutral |
| 2022-01-13 | 開始されました | Redburn | Buy |
| 2022-01-12 | 繰り返されました | BMO Capital Markets | Outperform |
| 2021-12-09 | 再開されました | Wells Fargo | Overweight |
| 2021-11-23 | アップグレード | Societe Generale | Hold → Buy |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Outperform |
| 2020-11-10 | 再開されました | Bernstein | Outperform |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-06-23 | アップグレード | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | アップグレード | Argus | Hold → Buy |
| 2020-05-18 | 再開されました | BofA/Merrill | Neutral |
| 2020-05-12 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-05-11 | 再開されました | Morgan Stanley | Overweight |
| 2020-04-20 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | ダウングレード | Societe Generale | Buy → Hold |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-02-06 | 開始されました | Mizuho | Buy |
| 2020-01-07 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | 繰り返されました | Cowen | Outperform |
| 2019-09-26 | アップグレード | Citigroup | Neutral → Buy |
| 2019-08-20 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | アップグレード | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | 開始されました | Goldman | Neutral |
| 2019-04-29 | アップグレード | BMO Capital Markets | Underperform → Market Perform |
すべてを表示
Abbvie Inc (ABBV) 最新ニュース
Berry Wealth Group LP Lowers Stake in AbbVie Inc. $ABBV - MarketBeat
AbbVie to invest $380 million in North Chicago campus to make next generation medicines - Daily Herald
AbbVie (ABBV) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
Chronic Idiopathic Constipation Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | ABBVIE, Eisai Co, Anji Pharma, Yuhan, Renexxion Ireland - Barchart.com
Evercore ISI Adjusts AbbVie Price Target to $233 From $228, Maintains Outperform Rating - marketscreener.com
AbbVie (ABBV) Completes $7.75 Billion Notes Offering - GuruFocus
GW&K Investment Management LLC Sells 6,207 Shares of AbbVie Inc. $ABBV - MarketBeat
Cytokines Market Global Forecast 2026-2032: Precise Treatments, Strategic Partnerships, and Supply Chain Resilience Fueling the $95+ Billion Market - GlobeNewswire Inc.
AbbVie Completes $8 Billion Senior Notes Financing Offering - TipRanks
Immunology, Obesity And Other Insights From The TD Cowen Healthcare Conference - Citeline News & Insights
US287YEG0 Bond Price and Chart — MUN:US287YEG0 - TradingView
AbbVie: Stabilizes Near $233 While Testing Resistance - Seeking Alpha
AbbVie: The Only Big Pharma Stock I'd Consider a Buy‑and‑Never‑Sell - The Globe and Mail
Uterine Fibroid Treatment Drugs Market Is Going to Boom Rapidly | - openPR.com
AbbVie stock price forecast: Stabilizes near $233 while testing resistance - Traders Union
ALLERGAN AESTHETICS HIGHLIGHTS MEDICAL WEIGHT LOSS (MWL) DATA AND THE CHANGING PROFILE OF PATIENTS - AbbVie News Center
Neurogenic Detrusor Overactivity Market Is Going to Boom Rapidly | Astellas Pharma Inc., Allergan plc (AbbVie Inc.) - openPR.com
Griffith & Werner Inc. Invests $2.64 Million in AbbVie Inc. $ABBV - MarketBeat
Picton Mahoney Asset Management Has $25.14 Million Stake in AbbVie Inc. $ABBV - MarketBeat
How Positive Crohn’s Phase 3 Data for SKYRIZI Could Impact AbbVie (ABBV) Investors - simplywall.st
Dimensional Fund Advisors LP Has $2.06 Billion Position in AbbVie Inc. $ABBV - MarketBeat
Cresset Asset Management LLC Sells 15,199 Shares of AbbVie Inc. $ABBV - MarketBeat
Perry Siatis Sells 18,668 Shares of AbbVie Inc (ABBV) - GuruFocus
AbbVie (ABBV) EVP Roopal Thakkar reports tax-withholding share disposition - Stock Titan
AbbVie CEO reports tax-withholding share disposition | ABBV SEC FilingForm 4 - Stock Titan
AbbVie (NYSE: ABBV) EVP reports tax-withholding share disposition - Stock Titan
AbbVie (NYSE: ABBV) EVP Perry Siatis sells 18,668 shares - Stock Titan
AbbVie (ABBV) CFO uses 21,638 shares to cover tax withholding - Stock Titan
AbbVie (ABBV) SVP Purdue disposes 2,692 shares for tax withholding - Stock Titan
AbbVie (NYSE: ABBV) EVP uses shares to cover tax withholding - Stock Titan
PRESCRIPTION DRUGS—M.D. Tenn.: Court rejects AbbVie’s challenge to Tennessee contract pharmacy law - VitalLaw.com
US287YEJ4 Bond Price and Chart — FWB:US287YEJ4 - TradingView
AbbVie at TD Cowen: Strategic Insights and Growth Outlook - Investing.com
AbbVie to Present at the Leerink Partners Global Healthcare Conference - Investing News Network
Harvest Portfolios Group Reduces Stake in AbbVie - National Today
Victory Capital Management Inc. Buys 120,490 Shares of AbbVie Inc. $ABBV - MarketBeat
State Farm Mutual Automobile Insurance Co. Sells 69,551 Shares of AbbVie Inc. $ABBV - MarketBeat
Hear AbbVie management live at Leerink global healthcare conference - Stock Titan
Level Four Advisory Services LLC Trims Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
AbbVie Hits $31 Billion in Skyrizi and Rinvoq Sales - TIKR.com
Fisher Asset Management LLC Decreases Holdings in AbbVie Inc. $ABBV - MarketBeat
CI Investments Inc. Has $41.19 Million Stake in AbbVie Inc. $ABBV - MarketBeat
AbbVie to invest $380M in new North Chicago API manufacturing facilities - Chicago Construction News
AbbVie’s New Data And Approval Test Growth And Valuation Story - Yahoo Finance
ABBV (NYSE: ABBV) Form 144: Director sale of 22,381 shares noted - Stock Titan
FDA Grants Orphan Drug Status to AbbVie's (ABBV) Neuroendocrine Carcinoma Treatment - GuruFocus
Why AbbVie Stock May Be the Ultimate Option for Dividend Investors - Nasdaq
AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® Subcutaneous Induction in Patients with Crohn's Disease - Investing News Network
AbbVie (ABBV) Reports Positive Phase 3 Results in Crohn's Diseas - GuruFocus
AbbVie Inc. (ABBV) Stock Analysis: A Healthcare Giant With A 7.16% Potential Upside - DirectorsTalk Interviews
AbbVie’s Skyrizi shows positive results in Crohn’s disease trial - Investing.com
Abbvie Inc (ABBV) 財務データ
収益
当期純利益
現金流量
EPS
0.55%
0.32%
大文字化:
|
ボリューム (24 時間):